Overview

This trial is active, not recruiting.

Condition copd
Treatment muscle biopsies
Sponsor Laval University
Collaborator GlaxoSmithKline
Start date January 2011
End date June 2015
Trial size 27 participants
Trial identifier NCT02557165, CRT114804

Summary

Muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (COPD) and can affect both respiratory and peripheral muscles. Impaired muscle regeneration is thought to be implicated in the process of muscle atrophy. In this study the investigators will evaluate muscle regenerative potential of the Vastus Lateralis (VL) and diaphragm of patients with COPD, compared to patients with normal lung function.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-crossover
Time perspective prospective
Arm
Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
muscle biopsies
Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
muscle biopsies
Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.

Primary Outcomes

Measure
Muscle satellite cell proliferation index
time frame: Sequential analyses performed over a period of 2 weeks after tissue collection.
Muscle satellite cell differentiation index
time frame: Sequential analyses performed over a period of 2 months after tissue collection.

Eligibility Criteria

Male or female participants from 40 years up to 80 years old.

Inclusion Criteria: - Patient with a scheduled thoracic surgery - ≥ 40 years - Smoking cessation ≥ 1 month - Smoking history ≥ 10 pack-year Exclusion Criteria: - Subjects who received either chemiotherapy or radiotherapy - Hypoxemia - Body weight loss ≥ 10% - Use of systemic corticosteroid in the last month

Additional Information

Official title Impact of Chronic Obstructive Pulmonary Disease on Peripheral and Respiratory Muscle Regeneration
Principal investigator Richard Debigare, PhD, PT
Description Preliminary results suggest that the activation and differentiation processes of satellite cells isolated from the VL of patients with COPD could be altered. The investigators propose to compare the regenerative potential of the VL and the diaphragm in 15 patients with COPD and 15 individuals with normal lung function undergoing a thoracic surgery. From muscle biopsies, satellite cells will be isolated and cultured to assess their proliferation and differentiation rates, and the expression level of myogenic effectors (MyoD, Myf5, myogenin, and MRF4). Alterations in these measurements will confirm the hypotheses that the regenerative potential is lower in both muscle groups in patients with COPD compared to controls and that in COPD, the regenerative potential is lower in VL compared to the diaphragm.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Laval University.